Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Catalyst PharmaceuticalsSTU:CN2 70 3-Year ROIIC % is 57.11 as of Dec. 2025, which is 4% above its 10-year median of 54.77. GuruFocus rates STU:CN2 with a GF Score™ of 70/100 and a GF Value™ of €21.84. The stock has 6 warning signs investors should review. Among 1,312 Biotechnology companies, Catalyst Pharmaceuticals ranks better than 72.87% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Catalyst Pharmaceuticals's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 57.11%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Catalyst Pharmaceuticals's 3-Year ROIIC % or its related term are showing as below:
STU:CN2's 3-Year ROIIC % is ranked better than 72.87% of 1312
companies
in the Biotechnology industry
Industry Median: -4.835
vs STU:CN2: 57.11
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Catalyst Pharmaceuticals 3-Year ROIIC % Related Terms
Catalyst Pharmaceuticals 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:CN2 vs PBLS, ELVN, RLAY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Catalyst Pharmaceuticals's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Catalyst Pharmaceuticals 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Catalyst Pharmaceuticals's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Catalyst Pharmaceuticals's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Catalyst Pharmaceuticals (STU:CN2) has a 3-Year ROIIC % of 57.11 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Catalyst Pharmaceuticals and its competitors. This is near median its historical median of 54.77. According to the industry distribution chart, Catalyst Pharmaceuticals ranks #356 out of 1312 companies in the Biotechnology industry, placing it in the top 27.1%.
Is Catalyst Pharmaceuticals' 3-Year ROIIC % too high?
Catalyst Pharmaceuticals' current 3-Year ROIIC % of 57.11 is near median its 10-year median of 54.77. Based on the distribution chart, Catalyst Pharmaceuticals ranks #356 out of 1312 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Catalyst Pharmaceuticals has a GF Score™ of 70/100, reflecting its overall financial health beyond just this single metric.
How does Catalyst Pharmaceuticals' 3-Year ROIIC % compare to PBLS and ELVN?
According to the Biotechnology industry distribution chart, Catalyst Pharmaceuticals ranks #356 out of 1312 companies for 3-Year ROIIC %. This puts Catalyst Pharmaceuticals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Catalyst Pharmaceuticals and its competitors. Catalyst Pharmaceuticals's current 3-Year ROIIC % is 57.11, which is near median its own 10-year median of 54.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Catalyst Pharmaceuticals stock overvalued right now?
Catalyst Pharmaceuticals (STU:CN2) has a current 3-Year ROIIC % of 57.11. The stock's GF Value™ is €21.84, compared to a current price of €27.50 — trading 25.9% above its estimated fair value. The current 3-Year ROIIC % is 57.11, which is near median its 10-year median of 54.77. Catalyst Pharmaceuticals' overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Catalyst Pharmaceuticals (STU:CN2), the current 3-Year ROIIC % is 57.11 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Catalyst Pharmaceuticals (STU:CN2) Overvalued in 2026?
Based on GuruFocus' analysis, Catalyst Pharmaceuticals stock appears to be overvalued.
The current stock price of €27.50 is trading 25.9% above its estimated GF Value™ of €21.84.
Key valuation signals for STU:CN2:
3-Year ROIIC %: 57.11 (near median its 10-year median of 54.77)
GF Value™: €21.84 vs. price of €27.50 (25.9% above fair value)
No single metric tells the full story. See the STU:CN2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
70GF Score
Get the complete analysis for STU:CN2
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:CN2 has been successfully added to your 
